Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Beam Therapeutics Inc. (BEAM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 Bellon Christine (Chief Legal Officer) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 388 shares @ $22.85, valued at $8.9k
08/09/2023 4 Simon Amy (Chief Medical Officer) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 391 shares @ $30.48, valued at $11.9k
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Company to Accelerate Development of BEAM-302 for Treatment of AATD; Program Now Expected to be First In Vivo Liver Regulatory Filing in First Quarter of 2024 Well-Capitalized with $1.1B in Cash, Cash Equivalents and Marketable Securities at the End of the Second Quarter of 2023 CAMBRIDGE, Mass., August 8, 2023"
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/21/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 4 Burow Kristina (Director) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 16,532 options to buy @ $34.33, valued at $567.5k
06/08/2023 4 COOPER GRAHAM K (Director) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 16,532 options to buy @ $34.33, valued at $567.5k
06/08/2023 4 Walsh Kathleen E (Director) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 16,532 options to buy @ $34.33, valued at $567.5k
06/08/2023 4 Fishman Mark (Director) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 16,532 options to buy @ $34.33, valued at $567.5k
06/08/2023 4 Ho Carole (Director) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 16,532 options to buy @ $34.33, valued at $567.5k
06/08/2023 4 MARAGANORE JOHN (Director) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 16,532 options to buy @ $34.33, valued at $567.5k
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/10/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 2 to Sales Agreement, by and between Beam Therapeutics Inc. and Jefferies LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to Beam Therapeutics Inc"
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-101 for Patients with Sickle Cell Disease Twenty-Year Industry Veteran, Gopi Shanker, Ph.D., Appointed as Chief Scientific Officer Well-Capitalized with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities at the End of the First Quarter of 2023 CAMBRIDGE, Mass., May 10, 2023"
04/21/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/19/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
04/05/2023 4 Evans John M. (CEO) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 5,161 shares @ $30.31, valued at $156.4k
Sold 6,493 shares @ $29.0935, valued at $188.9k
04/05/2023 4 Ciaramella Giuseppe (President & CSO) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 1,918 shares @ $30.31, valued at $58.1k
Sold 1,754 shares @ $29.0929, valued at $51k
04/05/2023 4 Bellon Christine (Chief Legal Officer) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 931 shares @ $30.31, valued at $28.2k
Sold 1,161 shares @ $29.0931, valued at $33.8k
04/05/2023 4 Simon Amy (Chief Medical Officer) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 4,445 shares @ $30.31, valued at $134.7k
Sold 10,493 shares @ $29.7664, valued at $312.3k
Sold 1,161 shares @ $29.0926, valued at $33.8k
04/05/2023 4 Burrell Terry-Ann (CFO) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Sold 2,454 shares @ $30.31, valued at $74.4k
Sold 2,186 shares @ $29.0931, valued at $63.6k
03/31/2023 4 Bellon Christine (Chief Legal Officer) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 17,500 shares @ $0
Exercised 6,272 options to buy @ $7.22, valued at $45.3k
Exercised 2,669 options to buy @ $7.22, valued at $19.3k
03/31/2023 4 Ciaramella Giuseppe (President & CSO) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 20,000 shares @ $0
Granted 40,000 options to buy @ $43.45, valued at $1.7M
03/31/2023 4 Evans John M. (CEO) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Small acquisition of 225 shares @ $0
Granted 56,250 shares @ $0
Granted 112,500 options to buy @ $43.45, valued at $4.9M
Exercised 13,850 options to buy @ $7.22, valued at $100k
03/31/2023 4 Simon Amy (Chief Medical Officer) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 20,000 shares @ $0
03/31/2023 4 Burrell Terry-Ann (CFO) has filed a Form 4 on Beam Therapeutics Inc.
Txns: Granted 20,000 shares @ $0
Granted 20,000 options to buy @ $43.45, valued at $869k
03/27/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
03/27/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
03/17/2023 SC 13G Temasek Holdings Ltd reports a 5% stake in Beam Therapeutics Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy